During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

Shares of Compass Therapeutics CMPX have skyrocketed 108.3% in a month after the company announced updates regarding its ...

Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...